Developing MetaGuideX, a rapid test for determining metastatic status in breast cancer.

开发 MetaGuideX，这是一种确定乳腺癌转移状态的快速测试。

• 批准号: 50425
• 金额: $ 26.75万
• 依托单位: METAGUIDEX
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=50425
• 关键词: Developing; MetaGuideX; rapid; test; determining

The management of breast cancer, which affects \>2 million new patients globally each year, is inadequate. In particular, we need better ways to:-detect whether metastasis (deadly spread of cancer to other parts of the body) has occurred-predict whether metastasis will occur in future-assess whether therapy is working well-detect the return of the tumour more quicklyIf we could do these better, doctors could decide on the best therapy for a given patient more quickly. The therapy is more likely to work and the patient is more likely to survive. Healthcare providers, such as the NHS, would save money by avoiding ineffective treatment, and a healthier population improves the national and global economy.Through our research into breast cancer metastasis we have discovered a protein present only in tumours with metastatic ability. This innovative biological marker could be used to tell doctors about the metastatic status of a tumour. Our innovative step is to turn this discovery into a diagnostic test, which we call MetaGuideX. Our test can be performed on the tumour itself, or on fragments of the cancer cells released into the bloodstream. The test meets an unmet clinical need, and can be used at the point of diagnosis, during treatment (to see if the therapy is effective) and during remission (to see if the tumour has returned).Our vision is to fundamentally change the way that breast cancer is managed, by introducing our test to hospitals and clinics, and setting up a 'service lab' to run the test for those who don't have the facilities to run it themselves.There are three important objectives we will achieve in order to lay down the foundations for our long-term ambition. We will:1.Develop a prototype diagnostic and test it on a panel of breast cancers to establish its performance and potential to impact breast cancer management2.Establish the proper regulatory systems and protocols needed for a diagnostics company. These complex regulations are enforced by UK and global agencies and we must implement them from the outset to prevent delay in getting the test into the clinic3.Engage with stakeholders to facilitate the uptake of an optimal test in the clinic.Achieving these objectives will allow us to gain further funding and expand the company, initially benefiting the NHS and then healthcare providers across the world, delivering social and economic impact as we grow.

乳腺癌每年在全球范围内影响到200多万新患者，对乳腺癌的管理是不够的。特别是，我们需要更好的方法来：-检测是否发生了转移（癌症向身体其他部位的致命扩散）-预测未来是否会发生转移-评估治疗是否有效-更快地检测肿瘤的复发如果我们能做得更好，医生就能更快地为给定的患者决定最佳治疗方法。治疗更有可能奏效，患者更有可能生存。医疗保健提供者，如NHS，将通过避免无效的治疗来节省资金，更健康的人口可以改善国家和全球经济。通过我们对乳腺癌转移的研究，我们发现了一种只存在于具有转移能力的肿瘤中的蛋白质。这种创新的生物标记物可以用来告诉医生肿瘤的转移状态。我们的创新步骤是将这一发现转化为诊断测试，我们称之为MetaGuideX。我们的测试可以在肿瘤本身或释放到血液中的癌细胞碎片上进行。该测试满足了未满足的临床需求，并可用于诊断点，治疗期间（看治疗是否有效）和缓解期间我们的愿景是从根本上改变乳腺癌的管理方式，通过将我们的测试引入医院和诊所，并设立一个“服务实验室”，为那些没有设备自己进行测试的人进行测试。为了为我们的长期目标奠定基础，我们将实现三个重要目标。我们将：1.开发一种原型诊断，并在一组乳腺癌上进行测试，以确定其性能和影响乳腺癌管理的潜力2.建立诊断公司所需的适当监管系统和协议。这些复杂的规定由英国和全球机构执行，我们必须从一开始就执行这些规定，以防止在将测试引入诊所方面出现延误3.与利益相关者合作，以促进在诊所中采用最佳测试。实现这些目标将使我们能够获得进一步的资金并扩大公司，首先使NHS受益，然后使世界各地的医疗服务提供者受益，随着我们的成长，带来社会和经济影响。